Evidence map›Paper›PMID 39158353›Full record

Trial reportJournal of the American Medical Informatics Association : JAMIA2025

Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.

Anna Northrop, Anika Christofferson, Saumya Umashankar, Michelle Melisko, Paolo Castillo, Thelma Brown, Diane Heditsian, Susie Brain, Carol Simmons, Tina Hieken and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyAdaptive Clinical Trial
In one paragraph

Trial report in Journal of the American Medical Informatics Association : JAMIA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anna NorthropDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.
Anika ChristoffersonDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.
Saumya UmashankarDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.ORCID 0000-0002-1147-8574
Michelle MeliskoDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA 94158, United States.
Paolo CastilloDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.
Thelma BrownPatient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States.
Diane HeditsianPatient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States.
Susie BrainPatient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States.
Carol SimmonsPatient Advocate, Breast Science Advocacy Core, University of California San Francisco, San Francisco, CA 94158, United States.
Tina HiekenDivision of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN 55905, United States.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, United States.
Candace MainorLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, United States.
Anosheh AfghahiDepartment of Medicine, University of Colorado, Aurora, CO 80045, United States.
Sarah TevisDepartment of Surgery, University of Colorado, Aurora, CO 80045, United States.
Anne BlaesDepartment of Medicine, Division of Hematology/Oncology, University of Minnesota, Minneapolis, MN 55455, United States.ORCID 0000-0002-5433-4810
Irene KangDepartment of Medical Oncology & Therapeutics Research, City of Hope Orange County, Irvine, CA 92618, United States.
Adam AsareDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.
Laura EssermanDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.ORCID 0000-0001-9202-4568
Dawn L HershmanDivision of Hematology/Oncology, Department of Medicine, Columbia University, New York, NY 10032, United States.
Amrita BasuDepartment of Surgery, University of California San Francisco, San Francisco, CA 94158, United States.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nola M. Hylton-Watson · 2017 to 2026
$22.9M
Time toxicity of cancer: the time demands of cancer-related activities and their impact on well-being and quality of lifeR01CA277714 · NCI · UNIVERSITY OF MINNESOTA · PI Rachel Isaksson Vogel, Julian Wolfson · 2023 to 2026
$1.4M
Proteomic aging in adults before and after cancer diagnosisR01CA267977 · NCI · UNIVERSITY OF MINNESOTA · PI PRIZMENT, ANNA · 2022 to 2024
$1.0M
Vasomotor symptoms of menopause and cardiovascular disease: What is the link?R21AG080503 · NIA · UNIVERSITY OF MINNESOTA · PI KELLER-ROSS, MANDA LINEA · 2023 to 2024
$413k
Cancer Center Survivorship Research ForumR13CA278261 · NCI · UNIVERSITY OF MINNESOTA · PI BLAES, ANNE H., SCHAPIRA, LIDIA · 2023 to 2023
$13k
Blue Cross Blue ShieldBreast Cancer Research FoundationGenentech and SkylineDX BVGilead, Caris Life Sciences, and Daiichi SankyoNCI NIH HHS P01 CA210961NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA267977NCI NIH HHS R01 CA277714NCI NIH HHS R13 CA278261NIA NIH HHS R21 AG080503NIH HHS P01CA210961NIH HHS R01CA267977Quantum Leap Healthcare CollaborativeSafeway FoundationUniversity of Minnesota Cancer Center P30CA077598William K. Bowes, Jr. Foundation, Give Breast Cancer the Boot, QLHC
6 · The paper itself

Abstract

objectivesWe describe the development and implementation of a system for monitoring patient-reported adverse events and quality of life using electronic Patient Reported Outcome (ePRO) instruments in the I-SPY2 Trial, a phase II clinical trial for locally advanced breast cancer. We describe the administration of technological, workflow, and behavior change interventions and their associated impact on questionnaire completion. MATERIALS AND

methodsUsing the OpenClinica electronic data capture system, we developed rules-based logic to build automated ePRO surveys, customized to the I-SPY2 treatment schedule. We piloted ePROs at the University of California, San Francisco (UCSF) to optimize workflow in the context of trial treatment scenarios and staggered rollout of the ePRO system to 26 sites to ensure effective implementation of the technology.

resultsIncreasing ePRO completion requires workflow solutions and research staff engagement. Over two years, we increased baseline survey completion from 25% to 80%. The majority of patients completed between 30% and 75% of the questionnaires they received, with no statistically significant variation in survey completion by age, race or ethnicity. Patients who completed the screening timepoint questionnaire were significantly more likely to complete more of the surveys they received at later timepoints (mean completion of 74.1% vs 35.5%, P < .0001). Baseline PROMIS social functioning and grade 2 or more PRO-CTCAE interference of Abdominal Pain, Decreased Appetite, Dizziness and Shortness of Breath was associated with lower survey completion rates. DISCUSSION AND

conclusionBy implementing ePROs, we have the potential to increase efficiency and accuracy of patient-reported clinical trial data collection, while improving quality of care, patient safety, and health outcomes. Our method is accessible across demographics and facilitates an ease of data collection and sharing across nationwide sites. We identify predictors of decreased completion that can optimize resource allocation by better targeting efforts such as in-person outreach, staff engagement, a robust technical workflow, and increased monitoring to improve overall completion rates.

trial registrationhttps://clinicaltrials.gov/study/NCT01042379.

Indexed as

Breast NeoplasmsPatient Reported Outcome MeasuresQuality of LifeFemaleHumansMiddle AgedNeoplasm StagingSurveys and QuestionnairesWorkflowclinical trialsimplementationpatient-reported outcomes

Identifiers

PMID39158353
PMCPMC11648710

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.